SCHEMBL2332245

SCHEMBL2332245

O=C(Cn1cccc1C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
RECQL P46063 2/20 0.49
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
ALOX12 P18054 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RAB9A P51151 2/20 0.46
STAT1 P42224 1/20 0.46
NPC1 O15118 1/20 0.46
MGAM O43451 1/20 0.46
AMY1A P0DUB6 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
GSK3B P49841 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6900631 0.87 MEN1 (0.60) MAPTALDH1A1KDM4ERECQLKMT2A
SCHEMBL28058971 0.85 RECQL (0.47) MAPTALDH1A1KDM4ERECQLKMT2A
SCHEMBL2336600 0.84 GSK3B (0.51) MAPTALDH1A1RECQLKMT2ALMNA
SCHEMBL2330773 0.82 KDM4E (0.70) MAPTALDH1A1KDM4ERECQLKMT2A
SCHEMBL2331508 0.81 MAPT (0.43) MAPTALDH1A1KDM4ERECQLKMT2A
SCHEMBL2330297 0.80 KDM4E (0.57) MAPTALDH1A1KDM4EKMT2ALMNA
SCHEMBL8942396 0.79 VEGFA (0.57) MAPTALDH1A1KDM4ERECQLKMT2A
SCHEMBL20916882 0.78 NPC1 (0.51) MAPTALDH1A1KDM4ERECQLKMT2A
SCHEMBL9685245 0.76 MAPT (0.58) MAPTALDH1A1KDM4EKMT2ALMNA
SCHEMBL2331167 0.76 IDO1 (0.49) MAPTKMT2ALMNAMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534155-B1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENT MANAGEMENT PTY LTD (AU) 2018-04-11 EP disclosed
US-9540387-B2 Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2017-01-10 US disclosed
CN-102844318-B Be used for the treatment of the compound of respiratory syncytial virus infection BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2016-04-13 CN disclosed
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections BIOTA SCIENT MANAGEMENT (AU) 2016-02-18 US disclosed
US-9163029-B2 Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2015-10-20 US disclosed
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2014-02-20 US disclosed
US-8604034-B2 Substituted imidazo[1,2-α]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-12-10 US disclosed
CN-102844318-A Compounds for treating respiratory syncytial virus infections BIOTA SCIENT MAN 2012-12-26 CN disclosed
EP-2534155-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS Biota Scientific Management Pty Ltd (AU) 2012-12-19 EP disclosed
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2011-08-25 US disclosed
WO-2011094823-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 MAPT 4436/4885ALDH1A1 609/4885KDM4E 4061/4885
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections FURIN, SQOR, SUCNR1 MAPT 4436/4885ALDH1A1 609/4885KDM4E 4061/4885
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 MAPT 4436/4885ALDH1A1 609/4885KDM4E 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.